SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CLDX Celldex Therapeudics
An SI Board Since September 2016
Posts SubjectMarks Bans Symbol
105 14 0 CLDX
Emcee:  Michael L Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
30But my fave early-stage project is the merTK program, and it would be cool to sescaram(o)uche-11/27/2019
29Next molecule to enter the clinic will be CDX-527, due before mid-year 2020. A scaram(o)uche-11/27/2019
280159 was derived from the Kolltan molecule, 0158, which exhibited pronounced injscaram(o)uche-11/27/2019
27The latest project to enter the clinic. Anti-kit, a kit inhibitor. CDX-0159, pscaram(o)uche211/20/2019
26Let's keep this board going, A good place where messages can be stored and smiddlepath-4/20/2019
25Didn't see that intraday dip to the low. Would have been buying. But at 0.scaram(o)uche-2/8/2019
24Firesaling big time now, though. Tempted. edit: bought a teeny position for 38tuck-2/8/2019
23reverse split, 1:15 No surprise, but surprised, here, that initial reaction is scaram(o)uche-2/8/2019
22Cool investigator-sponsored trial, "Platform Study for Prostate Researchingscaram(o)uche-2/8/2019
21Cancer Immunol Res. 2019 Jan 14. pii: canimm.0061.2018. doi: 10.1158/2326-6066.Cscaram(o)uche-1/16/2019
20So, you drive proliferation of dendritic cells and then drive their differentiatscaram(o)uche-1/15/2019
19Just parking, a tickle to follow up. Nothing to see here..... Immunol Cell Bioscaram(o)uche-1/15/2019
18Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domainscaram(o)uche-12/27/2018
17>> promotes survival in acute lymphoblastic leukemia (ALL) cells and is thscaram(o)uche-12/27/2018
16(So many moving parts! I could have chosen an easier company.) A close friend scaram(o)uche-12/27/2018
15If you stumble into this thread? I am not an expert on CLDX. I am learning as scaram(o)uche212/27/2018
14oooops, forgot that THE trial isn't listed under that cldx search........ cscaram(o)uche-12/27/2018
13Here is the antigen used for this clinician-sponsored trial (open label, primaryscaram(o)uche-12/27/2018
12I'll continue with other projects when I have time/inclination (today is dedscaram(o)uche-12/27/2018
11MerTK, a preclinical project (unleashing innate responses)....... ir.celldex.coscaram(o)uche112/26/2018
10OK, so that takes care of HER-3. Documented single agent activity, first stage scaram(o)uche-12/26/2018
9>> Durable complete response (CR) with CDX-3379 and cetuximab in a patientscaram(o)uche-12/26/2018
8CDX-3379 trial (combo with EGFR antagonist) in HNSCC......... clinicaltrials.goscaram(o)uche-12/26/2018
7Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epubscaram(o)uche-12/26/2018
6List of active trials, first two are company trials, last three are investigatorscaram(o)uche-12/26/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News